Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40%
Translational Vision Science & Technology · 2025
DOI: 10.1167/tvst.14.9.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2025. Verfasst von Jacques Hermes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Clinical Trials as Topic, Ophthalmology, Retinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- Institute of Physics, University of Freiburg, Freiburg, Germany.
- Freiburg Center for Data Analysis and Modelling (FDM), University of Freiburg, Freiburg, Germany.
Zitieren
APA
Hermes, J., & Steiert, B. (2025). Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40%. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.14.9.2
Vancouver
Hermes J, Steiert B. Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40%. Translational Vision Science & Technology. 2025. doi:10.1167/tvst.14.9.2
BibTeX
@article{Hermes2025,
author = {Hermes, Jacques and Steiert, Bernhard},
title = {Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40%},
journal = {Translational Vision Science & Technology},
year = {2025},
doi = {10.1167/tvst.14.9.2}
}
EUVIMED